Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation
ConclusionsMorbidly obese AF patients treated with rivaroxaban had comparable risk of ischemic stroke/systemic embolism and major bleeding as those treated with warfarin, but lower healthcare resource utilization and costs.
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Coumadin | Databases & Libraries | Eating Disorders & Weight Management | Healthcare Costs | Heart | Heart Transplant | Heart Valve Disease | Heart Valves | Ischemic Stroke | Obesity | Stroke | Transplant Surgery | Transplants | Warfarin